Hematologic Malignancy
Myelodysplastic Syndrome with Excess Blasts
CI-CAN-00003369MDS-EB · MDS-IB · RAEB · RAEB-1Explore in graph →
Hematologic23 active trials
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003369MDS-EB · MDS-IB · RAEB · RAEB-1Explore in graph →
Rankings
7 current ranking rows (latest year per scope). Each row lists the scope, the formula version, the value and the exact inputs that produced it.
| Metric | Scope | Rank / eligible | Δ | Value | Percentile | Confidence | Formula | Generated | Inputs |
|---|---|---|---|---|---|---|---|---|---|
| Publications, last 12 months | World · both sexes · all ages · latest · all malignant entities | #710 / 2,294 | = | 21 count | 69.1 | Medium confidence | ci-pubs-12m-v1 | Sep 29, 2026 | showformula: literature_counts.count WHERE window_key = 12m
inputs hash 6636ad9f834652e029647409 Trace lineage (admin) |
| Publications, last 5 years | World · both sexes · all ages · latest · all malignant entities | #694 / 2,873 | = | 118 count | 75.9 | Medium confidence | ci-pubs-5y-v1 | Sep 29, 2026 | showformula: literature_counts.count WHERE window_key = 5y (query stored per row)
inputs hash 531d42217f151c0dd79899a6 Trace lineage (admin) |
| Publication growth | World · both sexes · all ages · latest · all malignant entities | #176 / 286 | = | 1.02 ratio | 38.6 | Medium confidence | ci-pub-growth-v1 | Sep 29, 2026 | showformula: publications_12m / (publications_5y_prior / 5)
inputs hash 3385afecab0ace04e61b6db0 Trace lineage (admin) |
| Active clinical trials | World · both sexes · all ages · latest · all malignant entities | #419 / 1,654 | = | 23 count | 74.7 | Medium confidence | ci-active-trials-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) FROM trial_conditions JOIN clinical_trials WHERE cancer_id IN descendants(cancer) AND study_type = INTERVENTIONAL AND overall_status IN (RECRUITING, NOT_YET_RECRUITING, ENROLLING_BY_INVITATION, ACTIVE_NOT_RECRUITING)
inputs hash f2f5ed2084d93bba6dcb810e Trace lineage (admin) |
| Active Phase III trials | World · both sexes · all ages · latest · all malignant entities | #403 / 810 | = | 2 count | 50.3 | Medium confidence | ci-phase3-trials-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) … active statuses AND PHASE3 = ANY(phases)
inputs hash 56fba75197c8c0044b9e345f Trace lineage (admin) |
| Recruiting clinical trials | World · both sexes · all ages · latest · all malignant entities | #420 / 1,277 | = | 12 count | 67.2 | Medium confidence | ci-recruiting-trials-v1 | Sep 29, 2026 | showformula: COUNT(DISTINCT trial) … overall_status = RECRUITING AND study_type = INTERVENTIONAL
inputs hash 4352f89d0670b61272a585b3 Trace lineage (admin) |
| Sponsor concentration (HHI) | World · both sexes · all ages · latest · all malignant entities | #118 / 615 | = | 0.13 index (0–1) | 80.9 | Medium confidence | ci-sponsor-hhi-v1 | Sep 29, 2026 | showformula: Σ (active_trials_by_lead_sponsor / active_trials)² over the cancer and its descendants
|
Computed Ranks are competition ranks (ties share a rank). Percentile = share of eligible entities ranked at or below this one in the ranking direction.
"Deadliest" is ambiguous: annual deaths, age-standardized mortality rate, mortality-to-incidence ratio and 5-year survival rank cancers differently. CancerIndex publishes each as a separate metric.
inputs hash d0a365cf448b4492e5842c02
Unmet need · computed
No research-gap components for this entity